Queensland COVID-19 research

This page of Queensland’s research related to the COVID-19 pandemic is compiled from information provided by Queensland universities and research institutes.

1. SearchSearch by title, organisation, research details
2. Parent organisation (any) Australian Centre For Health Services Innovation (AusHSI) Bond University CQUniversity Griffith University James Cook University Mater Research QIMR Berghofer Medical Research Institute Queensland Health Queensland University of Technology The University of Queensland The University of Queensland, and The Prince Charles Hospital University of Southern Queensland University of Sunshine Coast University of the Sunshine Coast Wesley Medical Research
3. Sector or topic (any) Advanced manufacturing Antivirals Arts Bioeconomy Business and economics Clinical trials Community perceptions Creative industries Data science Diagnostics Drug development Drug discovery Education Emergency management Epidemiology Evidence based guidelines Exercise Hazard management Humanities Immunology Infection management Intervention evaluation Law Mental health and wellbeing Meta-analysis Modelling Neurological impairment Personal Protective Equipment (PPE) Prevention Public health Social media Social sciences Sun exposure Systematic review Tourism Treatment Urban design and town planning Vaccine Zoonotics

• Queensland hospitals begin testing drugs in COVID-19 clinical trial April 2020

  Queensland hospitals (see collaborations) have started testing two potential treatments on patients with COVID-19 as part of an international clinical trial involving The University of Queensland. Patients admitted to participating Queensland hospitals after testing positive for the disease were involved in the Australasian COVID-19 Trial (ASCOT) study, being led by the Doherty Institute in Melbourne. Queensland hospitals are working with researchers to help test the effectiveness of an HIV drug and a malaria medication for treating COVID-19 at 11 of the state’s hospitals and Wesley Medical Research. The Royal Brisbane and Womens Hospital pharmacy is approved by the Therapeutics Goods Australia to undertake the packing and distribution of the ASCOT study investigational medications to hospitals across Australia and New Zealand. The randomised response adaptive trial will allow researchers to objectively assess whether patients who receive a specific treatment fare better, worse or the same as patients who receive a different therapy. The ASCOT trial involves 2500 patients at more than 70 hospitals, covering every state and territory of Australia, and 12 hospitals in New Zealand.

  #Clinical trials

  Centre

  Centre for Clinical Research
  The University of Queensland

  Contact details

  Prof David Paterson
  d.paterson1@uq.edu.au
  +61 7 334 66074

  Collaborations

  • Royal Brisbane and Womens Hospital
  • Princess Alexandra Hospital
  • Caboolture Hospital
  • Cairns Hospital
  • Logan Hospital
  • Mackay Base Hospital
  • Mater Brisbane
  • Redcliffe Hospital
  • Sunshine Coast University Hospital
  • The Prince Charles Hospital
  • Townsville Hospital and Health Service
  • Wesley Medical Research
  • Trial lead: Peter Doherty Institute
  • Funders:
  • Royal Brisbane and Women’s Hospital Foundation
  • Australian Government
  • The Anthony Pratt Foundation
  • Wesley Medical Research
  • Minderoo Foundation
  • Health Research Council of New Zealand
  • Australian Partnership for Preparedness Research on Infectious Disease Emergencies